CHI3L1 and non-small cell lung carcinoma: Importantly, we detect an increased plasma CHI3L1 concentration that correlates with poorer overall survival in our in-house cohort of non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC) patients.